Request Demo

Last update 27 Jan 2026

Oxymetazoline Hydrochloride

Last update 27 Jan 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol, 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol

+ [40]

Target

α1A-AR

Action

agonists

Mechanism

α1A-AR agonists(Alpha-1a adrenergic receptor agonists)

Therapeutic Areas

Cardiovascular DiseasesEye DiseasesOtorhinolaryngologic Diseases+ [4]

Active Indication

BlepharoptosisErythemaRosacea+ [4]

Inactive Indication

PresbyopiaSpinal Cord InjuriesUrinary Incontinence

Originator Organization

Schering-Plough Canada, Inc.

Active Organization

Mayne Pharma Ltd.

Santen Pharmaceutical Co., Ltd.Santen SAS

+ [6]

Inactive Organization

Actavis, Inc.

Allergan UCBayer Healthcare LLC

+ [1]

License Organization

Aclaris Therapeutics, Inc.

Allergan plc

Santen Pharmaceutical Co., Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

Canada (31 Dec 1964)

RegulationOrphan Drug (European Union)

Structure/Sequence

Molecular FormulaC16H25ClN2O

InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N

CAS Registry2315-02-8

Clinical Trials associated with Oxymetazoline Hydrochloride

NCT07168148

/ RecruitingPhase 2IIT

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

This prospective, virtually administered trial conducted throughout the United States aims to evaluate a standardized protocol including the serial dilution of topical decongestants with concurrent topical steroids (triamcinolone), for elimination of dependence on topical decongestants.

Start Date10 Nov 2025

Sponsor / Collaborator

Washington University School of Medicine

NCT07000877

/ RecruitingPhase 4IIT

Nasal Decongestant Administration to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having General Anesthesia - a Low Risk Intervention. (NARWHAL)

The goal of this multicentre, double-blind, randomised controlled trial study is to learn if the use of a nasal spray to open the nasal passages and increase airflow before surgery can reduce the occurrence of perioperative respiratory adverse events in children with upper respiratory tract infection who are undergoing anesthesia.
The main questions it aims to answer are:
* Does use of a nasal decongestant (Oxymetazoline 0.05%) reduce perioperative respiratory adverse events during emergence (when waking up from anesthesia) or in the post-anesthesia care unit in children.
* Is it easy and acceptable to doctors, children and parents to use the nasal decongestant treatment? Researchers will compare the nasal decongestant to a placebo (a look-alike substance that contains no drug) to see if it works to reduce perioperative respiratory adverse effects.
Participants will:
* Take a nasal decongestant or a placebo prior to surgery (just before anaesthesia is given)
* Be monitored during and after surgery in the post-anaesthesia care unit for any perioperative respiratory adverse events.
* Be asked about how acceptable they found the treatment.

Start Date25 Jun 2025

Sponsor / Collaborator

Telethon Kids Institute

[+2]

NCT06911216

/ CompletedEarly Phase 1

A Multiple-Dose Pharmacokinetics (PK) Study of STN1013800 in Healthy Adults

This is to characterize STN1013800 active ingredient bioavailability following multiple-dose ocular administration of STN1013800 to both eyes in healthy adults.
It is a PK study with screening period of up to 28 days + dosing period of 7 days + Follow-up period of 2 days.
At present, there are no medicines for the treatment of acquired blepharoptosis in China.
Therefore, efficacy and safety phase III study is also currently being conducted.

Start Date17 Mar 2025

Sponsor / Collaborator

Santen Pharmaceutical Co., Ltd.

100 Clinical Results associated with Oxymetazoline Hydrochloride

100 Translational Medicine associated with Oxymetazoline Hydrochloride

100 Patents (Medical) associated with Oxymetazoline Hydrochloride

1,345

Literatures (Medical) associated with Oxymetazoline Hydrochloride

01 Jan 2026·JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Laser and energy‐based devices for treating rosacea ‐ a systematic review and network meta‐analysis

Review

Author: Herberger, Katharina ; Schneider, Stefan W. ; Nguyen, Lynhda ; Seeber, Nikolaus ; Sorbe, Christina

Summary:

Background and Objectives:

Rosacea is a chronic inflammatory condition affecting the central face. While laser and energy‐based devices (EBDs) are commonly used for managing vascular symptoms, comprehensive comparisons between systems are limited. This study aims to evaluate and compare the efficacy and safety of lasers and EBDs for rosacea through a systematic review and network meta‐analysis (NMA).

Methods:

Randomized controlled trials (RCTs) were identified from MEDLINE, CENTRAL, and Web of Science, with additional searches for ongoing trials. Primary outcomes included patient satisfaction, improvements in erythema and telangiectasia, and long‐term adverse events (AEs). Risk of bias (RoB) and publication bias were also assessed.

Results:

25 RCTs were included for qualitative analysis, and subsets contributed to the NMAs. Most studies exhibited unclear or high risk of bias, with a slight publication bias observed. Radiofrequency microneedling was more effective than pulsed dye laser (PDL) in terms of patient satisfaction (MD –1.32; 95 % CI –1.89 to –0.76) and erythema (MD –1.44; 95 % CI –1.96 to –0.91). The combination of oxymetazoline and PDL appeared superior for telangiectasia (MD –0.58; 95 % CI –1.03 to –0.14). AEs and discontinuation rates were comparable across treatments.

24 Dec 2025·Journal of Surgical Case Reports

Myopericytoma on the nasal turbinate

Article

Author: Guo, Guangming ; Vats, Ishani R ; Kumar, Naveen V ; Gervais, Jacob S ; Vats, Veena V

Abstract:

Myopericytoma is a mesenchymal tumour that shares characteristics with other soft tissue tumours including glomus tumours and myofibromas. These pericytic tumours show characteristic perivascular growth patterns (Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica 2021;113:70–84. https://doi.org/10.32074/1591-951X-213). Myopericytoma differentiates itself as it tends to have a spindle shape histologically, rather than an epithelioid shape as with the glomus variety. Myopericytoma rarely demonstrate malignant behaviour. A 67-year-old male presented to our clinic with complaints of increased frequency of right sided epistaxis for several months. The epistaxis episodes were controlled with oxymetazoline spray and manual pressure to the nasal tip. Office nasal endoscopy revealed a mass emanating from the anterior end of the right inferior turbinate. Complete excision was performed endoscopically. Histopathological analysis revealed myopericytoma, a rare tumour typically arising from the epithelium or submucosa. This case underscores the need for otolaryngologists to consider perivascular tumours in the differential diagnosis of intranasal masses as complete excision is recommended to avoid recurrence.

01 Dec 2025·Asia Pacific Allergy

Diagnosis and management of allergic rhinitis: An Indian expert consensus by otorhinolaryngologists

Review

Author: Bhalerao, Sudhir M. ; Bhatnagar, Kshitij ; Haldipur, Deepak ; Kumar Jain, Maneesh ; Gupta, Arvind ; Rao, A.V. Ramana ; Rathnaraajan Subramaniam, Sarrath ; Gure, Prasanta ; Nath, Biplab ; Panigrahi, Rajlaxmi ; Mukherjee, Anirudha ; Aggarwal, Nitish ; Vengelote, Ramakrishnan ; Baskar, Prasheetha ; Juvekar, Meenesh ; Narurkar, D.M. ; Mehta, Ravi T. ; Israni, Anil ; Kumara, Ajitha ; Tandon, Anurag ; Mahesh, S.G. ; Moitra, Mainak ; Kumar Sarkar, Swapan ; Sanyal, Debasis ; Rasool, Shahid ; Shashidhara Shetty, Anusha ; Rout, Khageshwar ; Pai, Vishwas K. ; Harishvel, V. ; Desai, Dipak ; Ramesh Kumar, S. ; Narayanamswamy, GN ; Prabhu Ganeshan, Arun ; Patel, Mehul S. ; Noohu, Sulphi ; Shetty, Adip ; Rai, Vikrant ; Sathe, Neelam ; Sethi, Sameer ; Kumar Ghosh, Swapan ; KP, Sunil Kumar ; Sahu, Narayan ; Dhond, Prakash V. ; Reddy, P. Venu Gopal ; Shetty, Shama ; Chary, Ch. Ramana ; Apparao, S.K.E. ; Ranjan Sarkar, Dhiraj ; Samantray, Kabikant ; Vijay Ghorpade, Chetan ; Kameswaran, Mohan ; Suri, Neeraj ; Mahadevan, Sankar ; Singh Yadav, Jagveer ; Pratap Singh, Bhanu ; Samanth, Rakshitha ; Jain, Anil ; Gananathan, G. ; Ramchandra Sirdesai, Praveen ; Mishra, K.N. ; Dutta, Smrity Rupa Borah ; Jaiswal, Ashok ; Nene, Milind

Background::

The prevalence of allergic rhinitis (AR) has increased progressively over the past several years. One of the vital objectives of management of AR is to provide satisfactory symptom control that improves the patient’s quality of life. Several classes of drugs, such as antihistamines, intranasal corticosteroids, decongestants, leukotriene receptor antagonists, and immunotherapy, have been developed over the past decades for more effective management of AR. Combinations of pharmacotherapies have also been advocated to treat AR.

Objective::

To develop clinical practice-relevant consensus statements from experts in the field of otorhinolaryngology after giving due consideration to the real-world clinical dilemmas, current evidence, and preferences of both physicians and patients.

Methods::

Expert otorhinolaryngologists (n = 61) from India were invited to develop the consensus statements based on the modified Delphi method.

Results::

Several consensus statements were framed based on evidence from clinical trials and expert insights and experience. One crucial statement was regarding the additional subgrouping of patients with intermittent or persistent AR, or mild, moderate or severe AR into “sneeze-runners” (sneezing, anterior rhinorrhea, itchy nose, and itchy eyes; more sensitization to pollens) and “blockers” (severe nasal blockage and thick nasal mucus which often leads to postnasal drip and breathlessness; higher sensitization to polyvalent house dust, house dust mites and fungi) since they have distinct clinical profiles and different treatment approach. Another critical consensus was on the use of the fixed-dose combination of fluticasone furoate and oxymetazoline hydrochloride nasal spray for the persistent and moderate-severe blocker phenotype of AR.

Conclusion::

This expert consensus will help physicians in their clinical practice and complement effective diagnosis and management of AR.

News (Medical) associated with Oxymetazoline Hydrochloride

08 Jan 2026

·www.prnewswire.com

RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%

BRIDGEWATER, N.J., Jan. 8, 2026 /PRNewswire/ -- RVL Pharmaceuticals, Inc. and its affiliates (together, "RVL") announces Santen Pharmaceutical Co., Ltd. ("Santen"), a leading ophthalmology company has obtained the manufacturing and marketing approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1% (generic name: oxymetazoline hydrochloride; development code: STN1013800; hereinafter the product), a treatment for acquired blepharoptosis (low-lying eyelids). This milestone expands access in Japan to the first approved non-invasive treatment for blepharoptosis, where treatment options have primarily been limited to surgical procedures. In the U.S. market, Upneeq® is the first and only FDA-approved prescription eye drop for acquired blepharoptosis (low-lying eyelids), and continues to demonstrate strong patient satisfaction, increased adoption, and channel diversification. "UPNEEQ® was developed to provide patients with a meaningful, non-invasive alternative to eyelid surgery," said Lori Deo, Chief Executive Officer of RVL Pharmaceuticals. "Our partnership with Santen allows us to extend this innovation to patients in Japan. Together, we are addressing a significant unmet need and helping advance new standards of care for acquired blepharoptosis." Approval in Japan was supported by a Phase 3, placebo-controlled, randomized, double-masked study conducted in Japan, the efficacy and safety of once-daily administration of the product were evaluated in patients with acquired blepharoptosis. The superiority of the product was demonstrated in the primary endpoint - a change from baseline at 2 hours after administration in MRD-1 (Marginal Reflex Distance-1, the margin between the upper eyelid and the center of the pupil)* at Day 14 after the start of treatment—in the once-daily group versus the placebo eye drop group. In addition, an exploratory analysis showed that improvement in MRD-1 persisted for more than 8 hours after instillation. No serious adverse effects or adverse effects leading to treatment discontinuation were observed during the study. In the Phase 3 clinical trial in Japan (once-daily instillation for 6 months), no trend toward weakening of the eyelid-lifting effect or rebound effect was observed. * In this clinical study, MRD-1 was defined as the distance from the center of the pupil to the upper eyelid margin, as determined from anterior segment photographs. About Upneeq® in the United States Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults. The product was approved in the US by the FDA in July 2020. Important Safety Information Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions. UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse. Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren's syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse. UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ. Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used. The most common adverse reactions with UPNEEQ (occurring in 1–5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache. This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full U.S. Prescribing Information for UPNEEQ. About RVL Pharmaceuticals RVL Pharmaceuticals, Inc operates a digitally enabled, vertically integrated commercial platform spanning product acquisition through order fulfillment, meeting consumers and healthcare providers where they are. Its lead product, Upneeq®, provides a non-surgical eyelift for adults with acquired ptosis. Upneeq® activates a muscle in the eyelids, lifting the lid for a more open and awake look. One drop daily is clinically proven to provide visible results in as fast as 5 minutes and lasts up to 8 hours. In July 2020, Osmotica Pharmaceuticals plc (due to a company name change, currently known as RVL Pharmaceuticals, Inc.), entered into an exclusive license agreement with Santen, covering the continued development, registration, and commercialization rights for RVL-1201, a 0.1% oxymetazoline hydrochloride ophthalmic solution, in Japan and certain other international markets. Santen has been developing the product as STN1013800. For more information, please visit . About Santen Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" – Exploring the secrets and mechanisms of nature in order to contribute to people's health – Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision." For more information, please visit Media Contact: Lippe Taylor [email protected] SOURCE RVL Pharmaceuticals, Inc 21% more press release views with Request a Demo

Phase 3Clinical ResultLicense out/inDrug Approval

20 Feb 2025

·www.pharmaindustrial-india.com

Cosette Pharmaceuticals Acquires Mayne Pharma to Expand Globally

Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited at AUD 7.40/share for a total consideration of approximately USD 430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recommended that its shareholders vote in favor of the transaction. The transaction is expected to close in the second quarter of 2025. “This acquisition marks a transformational step for Cosette, adding patented, high-growth products to solidify our leadership in women’s health in the US and expanding our reach globally. By combining Cosette’s strong portfolio with Mayne Pharma’s proven commercial expertise, the combined company will be well positioned to further invest in innovation, portfolio expansion and better serve our patients. We look forward to a timely closing and welcoming Mayne Pharma to the Cosette family,” said Apurva Saraf, President and CEO of Cosette Pharma. “Joining the Cosette team amplifies our shared mission to improve lives through innovative and accessible Women’s health and dermatology medicines. This transaction represents a unique opportunity for our employees, customers, and patients. Together, we will extend the reach of important therapies, drive innovation, and improve patient access,” said Shawn Patrick O’Brien, CEO, Mayne Pharma. The combination will create a leading women’s health and dermatology focused pharmaceuticals company in the U.S. with an established presence in international markets, utilizing the strengths of two industry players to drive innovation and expand access to women’s health therapies. Cosette will utilize its market-leading commercial and operational capabilities, backed by its 350+ strong team and a leading portfolio of women’s health and dermatology products alongside Mayne Pharma’s complementary strength in these specialty areas. Mayne Pharma is backed by a 480+ strong team, including highly effective and successful sales and marketing teams in both specialties. The combined company will have two state-of-the-art FDA -approved manufacturing sites – one each in Lincolnton, North Carolina and Salisbury, South Australia – to service patients globally. Upon close, Cosette will market 12 patent-protected products focused on women’s health and dermatology, including leading brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®, and several programs in clinical development.

Acquisition

21 Nov 2024

·www.businesswire.com

Nasal Sprays Help Alleviate Nasal Congestion

AMERICAN FORK, Utah--( BUSINESS WIRE )--Today, Nathan Jones, CEO of Xlear Inc., a consumer hygiene products company, released this statement regarding the FDA’s proposal to remove popular over-the-counter decongestants, which contain the drug phenylephrine, from the market: “With the FDA concluding that this common decongestant isn’t effective, as we enter cold and flu season, and as families prepare to celebrate the holidays, many Americans need a new answer for the discomfort of sinus congestion,” Jones noted. “For people looking for help, the U.S. Centers for Disease Control (CDC) Guidance, ‘Relief for Symptoms of Colds and Coughs’, ‘instructions’ say to ‘use saline nasal spray to relieve congestion.’ i Similarly, CDC’s ‘Sinus Infection Basics’ say ‘How to Feel Better’ ‘use a . . . saline nasal spray,’” ii he pointed out. “You experience congestion because there is an irritant or pathogen in your upper airway that your body is trying to trap and wash away—your runny nose is your body flushing it out. Saline-based nasal sprays can help speed up that flushing, reduce pathogen load, and make it more effective. It’s commonsense: The faster the bad stuff is gone, the faster you feel better,” Jones added. “For congestion caused by pathogens—like colds and flus—people can enhance that effect by using a nasal spray that contains xylitol. A series of studies show xylitol (a natural sugar) deactivates and/or blocks the adhesion of many types of viruses and bacteria, to your airway cells,” iii Jones continued. Adhesion is the process by which a pathogen attaches to your tissue to initiate infection. Using a nasal spray with xylitol helps block adhesion of these pathogens. For example, a Randomized Controlled (clinical) Trial published in 2022, determined that a saline-nasal spray containing xylitol and other ingredients reduced the rate of COVID-19 infections by 62 percent above placebo. iv “Using a basic saline would be comparable to rinsing your hands with water; using a nasal spray with xylitol, like Xlear , would be comparable to washing your hands with soap. Expect more from your nasal hygiene products. Make sure they have xylitol so you can better and faster clean out the bad stuff while alleviating the congestion,” Jones added. Xlear nasal spray is a saline-based nasal spray containing xylitol. Xlear 12 Hour Nasal Decongestant is a saline-based nasal spray containing xylitol and the decongestant Oxymetazoline HCL. For more information on Xlear please visit www.xlear.com . ____________________________ i https://www.cdc.gov/antibiotic-use/media/pdfs/HCP-Relief-Colds-Cough-85by11-P.pdf ii https://www.cdc.gov/sinus-infection/about/index.html iii For example: T Kontiokari, M Uhari, M Koskela, Antiadhesive effects of xylitol on otopathogenic bacteria., Journal of Antimicrobial Chemotherapy , Volume 41, Issue 5, May 1998, Pages 563–565, https://academic.oup.com/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext - google_vignette ; Kontiokari, T., Uhari, M., & Koskela, M. (1998). Antiadhesive effects of xylitol on otopathogenic bacteria. The Journal of Antimicrobial Chemotherapy , 41 (5), 563–565, https://academic.oup.com/jac/article-abstract/41/5/563/652694?redirectedFrom=fulltext&login=false ; Jung, Kie Hoon. (2021). Antiviral Efficacy Against Virus Infections in Human-Derived Tracheal/Bronchial Epithelial Cells. Utah State University, https://xlrtmp.com/wp-content/uploads/2023/05/Antiviral-efficacy_USU2021.pdf ; Vega, J. C., et al., (2020). Iota carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. BioRxiv , https://professionals.xlear.com/portfolio/anti-adherence-of-viruses/ ; Ruiz, V., Rodríguez-Cerrato, V., Huelves, L. et al. Adherence of Streptococcus pneumoniae to Polystyrene Plates and Epithelial Cells and the Antiadhesive Potential of Albumin and Xylitol. Pediatr Res 69, 23–27, https://www.nature.com/articles/pr920116 - citeas . iv Damian Balmforth, et al., Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial., Journal of Clinical Virology, 155; 2022, https://www.sciencedirect.com/science/article/pii/S1386653222001809 .

100 Deals associated with Oxymetazoline Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01022	Oxymetazoline Hydrochloride	R01AA05 S01GA04 R01AB07	DB00935

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Blepharoptosis	United States	RVL Pharmaceuticals, Inc.	08 Jul 2020
Erythema	United States	Mayne Pharma Ltd.	18 Jan 2017
Hyperemia	Japan	Sato Pharmaceutical Co., Ltd.	01 Aug 2007
Nasal Obstruction	China	Changzhou Yabang Pharmaceutical Co., Ltd.	01 Jan 1992
Rosacea	United States	Bayer Healthcare LLC	30 May 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Blepharophimosis	Phase 3	Czechia	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	France	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Germany	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Hungary	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Italy	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Netherlands	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Poland	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	Spain	Santen SAS	30 Dec 2024
Blepharophimosis	Phase 3	United Kingdom	Santen SAS	30 Dec 2024
Fecal Incontinence	Phase 2	Hungary	RDD Pharma Ltd.	01 Nov 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05715346 (CTgov)	Phase 1/2	Blepharoptosis	33	LEV102 2.0% (LEV102 Topical Gel, 2.0%)	ltommmnawy = myhovafrof wohruxndmd (nflcufbcmv, fnqvsoeoti - tgywcjwnoi) View more	-	13 Nov 2024
				LEV102 1.0% (LEV102 Topical Gel, 1.0%)	ltommmnawy = hjlnqitoyt wohruxndmd (nflcufbcmv, gmwujuiuln - lokoywfjcj) View more
NCT04831047 (CTgov)	Phase 4	Eye Redness \| Conjunctivitis \| Blepharoptosis	114	Oxymetazoline hydrochloride 0.1% ophthalmic solution (Upneeq Group)	gqriowtttx(rnhibwejvf) = tzvwfppucx izdcqbzfqh (mgwvcsopxk, 1.1) View more	-	24 Apr 2023
				Placebo (Control Group)	gqriowtttx(rnhibwejvf) = wbjhxtipqe izdcqbzfqh (mgwvcsopxk, 0.8) View more
NCT04831047 (Pubmed \| J Plast Reconstr Aesthet Surg)	Not Applicable	Eye Redness \| Conjunctivitis \| Blepharoptosis	114	Topical oxymetazoline 0.1%	pvwcwkdmlb(hwqyipwwbh) = lwkpovypos snmpchbgsb (aifudlsukh )	Positive	09 Feb 2023
NCT04153188 (CTgov)	Phase 4	Rosacea	34	The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream)	fbikqnssug(sophbqehaw) = afmfgefowm vrnpfihawi (rxuxmqcpmv, 1.0) View more	-	18 Mar 2022
				Oxymetazoline HCL 1% Cream (Oxymetazoline HCL 1% Cream)	fbikqnssug(sophbqehaw) = ieeohoiija vrnpfihawi (rxuxmqcpmv, 1.0) View more
NCT01848041 (CTgov)	Phase 1/2	Blepharoptosis	46	RVL-1201 (RVL-1201 Once Daily)	dzdxrfdiog(mluyevwebb) = jbwmwvwkwo gqiqlxukgb (tmxixjigup, 5.07) View more	-	22 Jul 2021
				RVL-1201 (RVL-1201 Twice Daily)	dzdxrfdiog(mluyevwebb) = vodzvlmvue gqiqlxukgb (tmxixjigup, 4.64) View more
NCT03954444 (CTgov)	Phase 3	Rosacea	1,105	Oxymetazoline Hydrochloride (Oxymetazoline Hydrochloride Cream, 1%)	bbdbzpzkxo: Mean Difference (Net) = 2.7 (90% CI, -2.6 to 8.0)	-	23 Jun 2021
				Rhofade Cream, 1% (RHOFADE Cream, 1%)
NCT03228914 (CTgov)	Phase 4	Hemorrhage \| Nasal Polyps	20	Oxymetazoline (Oxymetazoline)	rnedyqvvxv(cpwjmvhhor) = rmwtuiintk pyktpkixjk (txnzsqwtxv, 0.19) View more	-	13 Jan 2021
				Epinephrine (Epinephrine)	rnedyqvvxv(cpwjmvhhor) = nxrbfxmhnt pyktpkixjk (txnzsqwtxv, 0.15) View more
NCT03352323 (CTgov)	Phase 3	Rosacea \| Erythema	50	Oxymetazoline	oequanaqmi = zetnfikktj yrwrfrttod (bivbbrebqb, cpthgmkvay - ddbcjgofqx) View more	-	05 Jan 2021
NCT02780115 (CTgov)	Phase 2	Presbyopia	151	AGN-190584 Vehicle	xyhuytyhuv(xidgcrdrhy) = yrdcfbvmnm hktuhfkqeu (diodsgamdz, 1.03) View more	-	22 Dec 2020
NCT02595528 \| NCT02780115 (PA039, AAO2020)	Phase 2	Presbyopia	-	Pilocarpine 1.0%/Oxymetazoline 0.05%	czjnumnrqv(gazxzfybbw) = hksrtcqvcr ldambyufbu (hgqxfiysgz )	Positive	13 Nov 2020
				Pilocarpine 1.5%/Oxymetazoline 0.125%	czjnumnrqv(gazxzfybbw) = rqhxsufpbx ldambyufbu (hgqxfiysgz )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis